Iovance Biotherapeutics (IOVA) FDA Suspending Clinical Trial Case

• On December 27, 2023, Iovance (IOVA) announced that, on December 22, 2023, the FDA had placed a clinical hold on a Company’s clinical trial.

• On it, $OIVA fell 18,67%, losing $424M+ of shareholder value.

• Investors may have grounds to suspect Iovance of a failed clinical trial, which led to their losses.

On December 27, 2023, Iovance announced that, on December 22, 2023, U.S. FDA had placed a clinical hold on the Company’s trial of lead product candidate for the treatment of metastatic non-small cell lung cancer.

Iovance advised that the FDA’s decision to place the clinical hold was in response to a recently reported Grade 5 (fatal) serious adverse event.

On this news, $IOVA fell 18,67% and lost over $424 million of its market capitalization, seriously damaging shareholders.

Considering all the information, investors might have grounds to suspect Iovance of facing a significant delay in bringing a product to market, which led to their losses.

The case is already under investigation by at least one of the reputable law firms.